Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDX013 for Hyperkalemia in CKD
NCT04780841Phase 2Completed
- Sponsor
- Ardelyx
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RDX013 in hyperkalemia, sponsored by Ardelyx. Started Jan 2021; status: completed.
02
Drugs
RDX013
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT04780841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780841.